Navigation Links
Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
Date:1/12/2012

SAN DIEGO, Jan. 12, 2012 /PRNewswire/ -- Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced the initiation of a Phase 1b study designed to evaluate the safety of MP4CO treatment in patients with sickle cell disease. MP4CO is designed to deliver therapeutic levels of carbon monoxide (CO) to patients suffering from a sickle cell crisis. This initial study will involve patients who are not currently undergoing a painful vaso-occlusive crisis. Preclinical studies show that carbon monoxide stabilizes the hemoglobin of patients with sickle cell disease and prevents the sickling of red blood cells.

"We are encouraged by the preclinical data on MP4CO and look forward to evaluating the safety and potential efficacy of this therapy in helping alleviate pain associated with a sickle cell crisis, while also potentially reducing the severity and duration of a crisis," said Dr. Jo Howard, at Guy's and St Thomas' Hospital, London, UK. "There is currently a dearth of treatments for painful vaso-occlusive crises associated with sickle cell disease, and MP4CO represents a potential treatment option for these patients."

The clinical trial is a multi-center, randomized, double-blind, controlled study that will enroll approximately 32 clinically stable adult patients with sickle cell disease who are not undergoing a painful vaso-occlusive crisis. The trial will be conducted at four sites across three countries, including the United Kingdom, France and Jamaica. The primary objective of the study is to establish the safety of treatment with MP4CO. The study will comprise ascending dose levels in five groups of single dose infusions followed by three groups of fractionated doses.

"This trial initiation is a key step towards providing a treatment to patie
'/>"/>

SOURCE Sangart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sangart Initiates Phase 2b Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
2. Sangart Announces Closing of $50 Million Series G Financing
3. Sangart, Inc. Receives U.S. Orphan Drug Designation for use of MP4CO in Patients with Sickle Cell Disease
4. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
5. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
6. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
7. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
8. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
9. Sumagen Initiates Clinical Testing of Omnia Biologics Manufactured HIV Vaccine
10. Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
11. Zimmer Initiates Quarterly Dividend and Announces New Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... --  Millar, Inc. , a leader in catheter-based and ... of Craig Thummel , President/CEO and member of ... to the Company. The Company also announced its leadership ... Executive Management team as his successors. The Board of ... of Sales and Marketing, as President, and also a ...
(Date:6/30/2015)... 2015 Dipexium Pharmaceuticals, Inc. (Nasdaq: ... on the development and commercialization of Locilex® (pexiganan ... previously announced underwritten public offering of 1,480,000 shares ... over-allotment option in full to purchase an additional ... net proceeds to Dipexium are expected to be ...
(Date:6/30/2015)... , June 24, 2015 ... the addition of the "Global Array Instruments ... The global array instruments market to grow ... period 2014-2019 The global array instruments market ... protein microarrays, and others including tissue microarrays and ...
Breaking Medicine Technology:Millar, Inc. Announces Leadership Changes 2Millar, Inc. Announces Leadership Changes 3Dipexium Announces Closing of Public Offering of Common Stock 2Dipexium Announces Closing of Public Offering of Common Stock 3Global Array Instruments Market 2015-2019 - Advances in Personalized Medicines with Affymetrix, Agilent Technologies & Illumina Dominating 2
... Biosciences, Inc., a privately held company leading the development ... Steven L. Zelenkofske, D.O., F.A.C.C., Senior Vice President and ... College of Chest Physicians (ACCP) Coagulation and Heart Disease ...  The abstract is titled "Sustained Inhibition of Factor IXa ...
... JEDDAH, Saudi Arabia, Nov. 2, 2010 The Saudi ... it has signed an agreement with Varian Medical Systems ... for magnetic resonance-guided radiation therapy (MRgRT™). Under ... treatment solution that combines IMRIS, unique movable magnetic resonance ...
Cached Medicine Technology:Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010 2Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010 3Saudi Arabia's King Abdullah International Research Center Signs With Varian Medical Systems and IMRIS for Future Technology for Use in Radiotherapy 2Saudi Arabia's King Abdullah International Research Center Signs With Varian Medical Systems and IMRIS for Future Technology for Use in Radiotherapy 3Saudi Arabia's King Abdullah International Research Center Signs With Varian Medical Systems and IMRIS for Future Technology for Use in Radiotherapy 4
(Date:6/30/2015)... ... June 30, 2015 , ... ... Rehab”. The video focuses on the rehab center’s patients and their experiences at ... the best quality of services available. Each patient attests to the high rating, ...
(Date:6/30/2015)... ... June 30, 2015 , ... According to a June 15th report ... study how sensory stimuli can be used to “decrease children’s anxiety and negative responses ... with autism, will compare patient experience in a “typical dental environment” with one that ...
(Date:6/30/2015)... Long Beach, CA (PRWEB) , ... June 30, 2015 , ... ... Sea Skilled Nursing”, which features multiple patient and family member testimonials. Medicare rated the ... the country. Broadway plans to use the video to give future patients a firsthand ...
(Date:6/30/2015)... New York, NY (PRWEB) , ... June 30, ... ... international shipping when buying eyeglasses online , finally its here, ... and offer express shipping rates, for many location, ask about shipping with DHL ...
(Date:6/30/2015)... New York (PRWEB) , ... June 30, 2015 ... ... ( http://www.xareltolawsuit2015.com/ ) currently pending in a federal multidistrict litigation now underway in ... Court convenes its next monthly Status Conference. According to the Court’s calendar, that ...
Breaking Medicine News(10 mins):Health News:Patients of University Post-Acute Rehab Support Five-Star Rating in New Video 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 3Health News:Broadway by the Sea Video Promotes Top Quality Service 2Health News:Eyeglasses Online - Express Glasses Announcing New International Shipping Using DHL 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 3
... the cost of such tests is a potential stumbling block, ... the heart arteries for calcium deposits can help predict future ... that adding such scans to routine checkups would be worth ... of potential heart trouble, said Dr. Diane Bild, deputy director ...
... Michael D. Farley has,joined the Lupus ... Washington,DC as the organization,s Chief Operating Officer, ... overall organizational administration and,field development. Farley has ... including serving most recently as the,interim CEO ...
... Inc.,(Nasdaq: EMAG ), a leader in ... healthcare networks, announced today that its,HeartSuite(TM) VERICIS(R) ... for,Cardiology PACS*. HeartSuite is Emageon,s comprehensive suite ... information,management, hemodynamic monitoring, advanced visualization and content,management. ...
... PURCELLVILLE, Va., March 26 At a panel,discussion ... Force Colonel,Mike Turner, a candidate for U.S. Congress ... for Professor Judy Feder, his opponent,in the June ... Frank,Wolf in what is expected to be a ...
... Courses Improve Patient Care and Address State Regulations, ... Care Compliance,Strategies, Inc.), the leading provider of online ... with University,HealthSystem Consortium (UHC) to deliver a suite ... 11 courses with multimedia content and,healthcare specific case ...
... of Other Medicare Providers at Risk, WASHINGTON, ... drug plans (PDPs) pay drugstores twice as fast,as ... and its,beneficiaries at least $3.3 billion over the ... (PwC) that was commissioned by the,Pharmaceutical Care Management ...
Cached Medicine News:Health News:Calcium Scans Help Predict Coronary Risk 2Health News:Michael D. Farley Appointed Chief Operating Officer of Lupus Foundation of America, Inc. 2Health News:Emageon Receives 'Best in KLAS' Cardiology PACS Award 2Health News:Democrat Mike Turner Backs Single-Payer Healthcare; Opponent Feder Undecided 2Health News:HCCS Partners With UHC to Deliver Cultural Competency Courses 2Health News:HCCS Partners With UHC to Deliver Cultural Competency Courses 3
The URCA (Uric acid) method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of uric acid in serum, plasma and urine....
For the quantitative in vitro determination of apolipoprotein A-1 (apo A-1) in serum and plasma. For use as an aid if assessing the risk of coronary artery disease....
The GGT method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of g-glutamyl transferase activity in serum and plasma...
For the quantitative in vitro determination of Triglycerides in serum and plasma....
Medicine Products: